Related Experiment Video
Updated: Apr 6, 2026
Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics
Published on: May 11, 2016
Silencing JARID1B suppresses oncogenicity, stemness and increases radiation sensitivity in human oral carcinoma
Chun-Shu Lin1, Ying-Chin Lin2, Bamodu Oluwaseun Adebayo3
1Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Purpose:
Oral squamous cell carcinoma (OSCC) is a major cause of human mortality globally and radiotherapy is one of the main treatment modalities, however its therapeutic effect is often limited by radioresistance. JARID1B is an epigenetic factor with reported oncogenic potential in various cancer types. We investigated the effect of JARID1B inhibition on migration and invasion of human OSCC cell lines, as well as on clinical patients' outcome.
Materials And Methods:
Wound healing, matrigel invasion, Sulforhodamine B, and spheroid formation assays were used to characterize the signaling pathways of shJARID1B in response to radiation treatment. We evaluated the prognostic relevance of Jarid1b expression in a cohort of 81 OSCC patients.
Results:
Human OSCC cell lines, including SAS, HSC3, Cal27, TW2.6 and SCC4 cells, were used. shJARID1B cells significantly inhibited migration and invasion ability compared to their vector or wild type counterparts. Silencing shJARID1B significantly inhibited oral cancer stem cell activity and potentiated the tumor-inhibitory activity of radiation therapy in OSCC. Radiotherapy coupled with shJARID1B knockdown reduced mRNA levels of NQO1, KEAP1, NRF2, FOXO1, FOXO3, KLF4, OCT4, CD133, and Nanog in malignant OSCC cells. OSCC spheroid formation ability was markedly reduced in the shJARID1B cells. JARID1B overexpression is a dependent prognostic factor in OSCC patients.
Conclusions:
Silencing shJARID1B inhibits migration and invasion of human OSCC, reduces cancer stem cell activities and potentiates tumor-inhibiting radiotherapeutic effects. JARID1B knockdown prior to radiotherapy is a potential effective therapeutic strategy for the treatment of OSCC.
Insights
Inhibiting JARID1B in oral squamous cell carcinoma (OSCC) reduces cancer cell migration, invasion, and stem cell activity. This inhibition potentiates radiotherapy, offering a potential therapeutic strategy for OSCC patients.
Area of Science:
- Oncology
- Epigenetics
- Cancer Biology
Background:
- Oral squamous cell carcinoma (OSCC) poses a significant global health challenge, with radiotherapy efficacy often compromised by radioresistance.
- JARID1B, an epigenetic factor, has demonstrated oncogenic potential across various cancer types, suggesting its role in OSCC progression.
Purpose of the Study:
- To investigate the impact of JARID1B inhibition on the migration and invasion capabilities of human OSCC cell lines.
- To assess the effect of JARID1B inhibition on oral cancer stem cell activity and its synergy with radiotherapy.
- To determine the prognostic relevance of JARID1B expression in OSCC patients.
Main Methods:
- Utilized wound healing, Matrigel invasion, and spheroid formation assays to evaluate OSCC cell behavior.
- Employed shJARID1B to inhibit JARID1B expression in OSCC cell lines.
- Analyzed the expression of key genes involved in cancer stemness and radioresistance.
- Correlated JARID1B expression levels with patient outcomes in a cohort of 81 OSCC patients.
Main Results:
- JARID1B inhibition significantly reduced migration, invasion, and spheroid formation in OSCC cell lines.
- Silencing JARID1B enhanced the tumor-inhibitory effects of radiation therapy in OSCC models.
- Knockdown of JARID1B prior to radiotherapy led to decreased mRNA levels of genes associated with cancer stemness and radioresistance (e.g., NRF2, OCT4, CD133).
- JARID1B overexpression was identified as a significant prognostic factor in OSCC patients.
Conclusions:
- JARID1B inhibition effectively suppresses OSCC cell migration, invasion, and stem cell characteristics.
- Combining JARID1B knockdown with radiotherapy presents a promising therapeutic strategy to improve treatment outcomes in OSCC.
- Targeting JARID1B may overcome radioresistance and enhance the efficacy of radiotherapy for oral cancer.
More Related Videos
07:52In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity
Published on: November 2, 2020
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:40Cancer Stem Cells and Tumor Maintenance
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene